In patients with PD-L1 negative metastatic cervical squamous cell carcinoma at primary diagnosis, do you add pembrolizumab, atezolizumab, or no immunotherapy to combination platinum/taxane/bevacizumab therapy?
The subset analysis of KEYNOTE 826 suggests no benefit in patients with CPS <1, but BEATcc included IO regardless of PD-L1 status.
Community PollStarted
In a patient with metastatic, PD-L1 negative cervical cancer at initial diagnosis, what immunotherapy do you include in their systemic therapy regimen?
43 physicians have voted
Join Mednetto vote and see how they answered.
1 Answer
Mednet MemberInvited Expert
Gynecologic Oncology · Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
Answered on
You are correct that the data is not crystal clear in these patients, which means it is reasonable to consider doing either platinum/taxane/bev or platinum/taxane/bev/immunotherapy. Personally, I find that when giving all 4 agents at once, patients do experience more toxicity. So in my practice for CPS <1, I tend to prefer the triplet therapy in order to limit toxicity and save immunotherapy for later in their treatment course (i.e., when there is persistent or recurrent disease).
In other diseas...
Join for free or sign in to see the full answer